- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04534673
Pegylated Interferon Lambda for Treatment of COVID-19 Infection
Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial
A randomized, open-label, 2 arm, pilot trial of Lambda 180 mcg administered subcutaneously once weekly, for up to two weeks (2 injections at most), in addition to standard supportive care, compared to standard supportive care alone, in a population of COVID-19 infected patients.
patients will be randomized according to 1:1 ratio to one of the 2 trial arms: Lambda 180 mcg S.C + standard care (intervention arm) or standard care only (control arm).
Study Overview
Detailed Description
Recently, a novel coronavirus (SARS-CoV-2) has been identified as the causative pathogen of a rapidly spreading infection associated with pneumonia and severe acute respiratory syndrome (COVID-19), for which there is currently no approved therapy. Interferon Lambda (IFN Lambda) is a type III interferon with broad anti-viral activity and receptor distribution limited to the respiratory and gastrointestinal epithelium. Studies in animal models suggest that IFN Lambda may ameliorate infection with respiratory viruses such as influenza coronaviruses. The WHO has recently included pegylated interferon lambda in its landscape analysis of potential therapeutics for COVID-19.
In this randomized, open-label, 2 arms, pilot trial, up to 40 patients diagnosed with COVID-19 and mild to moderate respiratory infection, will be randomized to one of 2 treatment arms in 1:1 ratio: 1. Lambda 180 mcg administered S.C once weekly, for up to two weeks (2 injections at most) + standard care, Or 2. Standard care alone.
Efficacy of Lambda will be assessed by PCR analysis for COVID-19 (Fluxergy, Irvine CA), from respiratory secretions obtained by nasopharyngeal and oropharyngeal swabs, collected consecutively at day 1, 3, 5, 7, 10, 14 and 21 following initial diagnosis or until patients are discharged following achievement of two consecutive PCR negative tests for COVID-19. Safety and tolerability of Lambda will be assessed by adverse event (AE) monitoring, vital signs assessment and clinical laboratory tests (CBC, and extended chemistry panel).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ohad Etzion, MD
- Phone Number: +972-8-6403330
- Email: ohadet@clalit.org.il
Study Contact Backup
- Name: Ruthie Bekore
- Phone Number: +972-8-6244240
- Email: Ruthieb@clalit.org.il
Study Locations
-
-
-
Be'er Sheva, Israel
- Soroka UMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female and male patients over the age of 18.
- Confirmed COVID-19 infection by PCR analysis
- Hospitalized at Soroka University Medical Center.
- Display mild to moderate symptoms of respiratory infection (Temperature <39.0 oC, respiratory rate < 25, O2 % Sat > 95% in room air or with supplemental oxygen through nasal cannula, P/F ratio > 150).
- Willing and able to convey informed consent.
- Willing and able to comply with all study procedures
- Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.
For females: 2 of the following contraceptive methods, with at least 1 being a barrier method:
- Hormonal contraceptives for ≥ 27 days before dosing
- Intrauterine device (IUD) in place ≥ 27 days before dosing
- Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening
- Surgical sterilization of the partner (vasectomy ≥ 1 month before screening) Female patients must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start of investigational product.
For males:
- Surgical sterilization (vasectomy ≥ 1 month before screening) Or
Both of the following contraceptive methods from screening:
- Consistently and correctly use a condom
- Partner must use a hormonal contraceptive or a nonhormonal barrier method (IUD or diaphragm with spermicide or cervical cap with spermicide).
Exclusion Criteria:
- Treatment with interferons (IFNs) immunomodulators and/or immunosuppressive or B-cell depleting medications within 12 months before screening.
- Previous use of Interferon Lambda. Patients who previously participated in a clinical trial of Interferon Lambda but are confirmed to have received placebo or another non-Lambda IFNs are allowed.
- History or evidence of any intolerance or hypersensitivity to IFNs.
- Patients with respiratory infection requiring invasive or non-invasive ventilatory support (bipap or intubation and mechanical ventilation).
- Participation in a clinical trial with use of any investigational drug within 30 days before screening.
History of any of the following diseases or conditions:
- Advanced or decompensated liver disease (presence or history of bleeding varices, ascites, encephalopathy or hepato-renal syndrome)
- Immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) that requires more than intermittent nonsteroidal anti-inflammatory medications for management or that requires use of systemic corticosteroids in the 6 months before screening (inhaled asthma medications are allowed).
- Retinal disorder or clinically relevant ophthalmic disorder.
- Any malignancy within 5 years before screening. Exceptions are superficial dermatologic malignancies (e.g., squamous cell or basal cell skin cancer treated with curative intent).
- Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease (including history of angina, myocardial infarction, or interventional procedure for coronary artery disease), or cardiac rhythm disorder.
- Chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) associated with functional impairment.
- Pancreatitis.
- Severe or uncontrolled psychiatric disorder, e.g., depression, manic condition, psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and relapse of substance abuse.
- Active seizure disorder defined by either an untreated seizure disorder or continued seizure activity within the preceding year despite treatment with anti-seizure medication.
- Bone marrow or solid organ transplantation
- Other significant medical condition that may require intervention during the trial (such as uncontrolled diabetes or thyroid disease) Patients with any serious condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed. Patients for whom participation in the trial would increase their risk.
- Current eating disorder
- Current alcohol abuse (excessive alcohol intake, defined as follows: >20 g/day for females [1.5 standard alcohol drinks] or >30 g/day for males [2.0 standard alcohol drinks]. A standard drink contains 14 g of alcohol: 360 mL of beer, 150 mL of wine, or 45 mL of spirits
- Drug abuse within the previous 6 months before screening, with the exception of cannabinoids and their derivatives
Any of the following abnormal laboratory test in the 12 months prior to enrollment
- Platelet count <90,000 cells/mm3
- White blood cell (WBC) count <3,000 cells/mm3
- Absolute neutrophil count (ANC) <1,500 cells/mm3
- Hemoglobin <11 g/dL for women and <12 g/dL for men
- Estimated creatinine clearance (CrCl) < 50 mL/min by Cockroft-Gault formulation
- ALT and/or ALT levels > 10 times the upper limit of normal
- Bilirubin level ≥ 2.5 mg/dL unless due to Gilbert's syndrome
- Serum albumin level <3.5 g/dL
- International normalized ratio (INR) ≥1.5 (except patients maintained on anticoagulant medications)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Pegylated interferon lambda + Standard of care treatment
|
Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
Other Names:
|
No Intervention: Control group
Standard of care treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral shedding in days since initial diagnosis
Time Frame: 21 days
|
The duration of viral shedding in days since initial diagnosis, as determined by RT-PCR to COVID-19.
|
21 days
|
Rate of adverse events and severe adverse events
Time Frame: 21 days from entry
|
Rate of treatment-emergent and treatment-related severe adverse events (SAEs)
|
21 days from entry
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to clinical recovery
Time Frame: 72 Hours
|
the time (in hours) from initiation of trial treatment (Lambda or standard care) until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours.
|
72 Hours
|
Rate of non-invasive or mechanical ventilation
Time Frame: 28 Days
|
Requirement for non-invasive (bipap) or mechanical ventilation
|
28 Days
|
Length of hospital stay
Time Frame: 28 Days
|
length of hospital stay from admission to discharge
|
28 Days
|
All-cause mortality
Time Frame: At day 28 following admission to the hospital
|
All-cause mortality
|
At day 28 following admission to the hospital
|
Undetectable COVID-19 virus levels
Time Frame: At days 7,14 and 21 from admission
|
Rate of undetectable COVID-19 virus levels at different days
|
At days 7,14 and 21 from admission
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ohad Etzion, MD, Soroka Univeersity Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0129-20-SOR
- SCRC200006 (Other Identifier: Soroka Clinical Research Center)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Lambda 180 mcg S.C
-
Beijing Bio-Fortune Ltd.Completed
-
PharmaEssentiaCompleted
-
AstraZenecaCompletedRelative BioavailabilityUnited States
-
Attikon HospitalAHEPA University Hospital; University Hospital, AlexandroupolisCompleted
-
Tianjin SinoBiotech Ltd.Completed
-
Cipla Ltd.CompletedBronchial AsthmaUnited States
-
BiocadCompletedMultiple Sclerosis, Relapsing-RemittingRussian Federation
-
The Wistar InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaboratorsCompleted
-
Amneal Ireland LimitedUnknown